Rizzo Alessandro, Cusmai Antonio, Gadaleta-Caldarola Gennaro, Palmiotti Gennaro
Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello," I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124 Bari, Italy.
Medical Oncology Unit, 'Mons. R. Dimiccoli' Hospital, Barletta (BT), Azienda Sanitaria Locale Barletta, 76121, Italy.
Expert Rev Gastroenterol Hepatol. 2022 Apr;16(4):333-339. doi: 10.1080/17474124.2022.2064273. Epub 2022 Apr 10.
Hepatocellular carcinoma (HCC) remains a frequently diagnosed malignancy worldwide, still representing an important cause of cancer-related death. Recent years have seen the emergence of novel systemic treatments for HCC patients, including immune checkpoint inhibitors (ICIs). Nonetheless, several questions regarding HCC immunotherapy remain unanswered, especially in terms of biochemical predictors of response.
In the current paper, we will discuss available evidence regarding predictive biomarkers of response to HCC immunotherapy. A literature search was conducted in January 2022 of Pubmed/Medline, Cochrane library, and Scopus databases.
The identification of predictive biomarkers represents an unmet need in HCC patients receiving ICIs. The HCC medical community is called to further efforts aimed to elucidate the effective role of PD-L1 expression, TMB, MSI, gut microbiota, and other emerging biomarkers.
肝细胞癌（HCC）仍是全球常见的诊断恶性肿瘤，仍是癌症相关死亡的重要原因。近年来，针对HCC患者出现了新型全身治疗方法，包括免疫检查点抑制剂（ICI）。尽管如此，关于HCC免疫治疗的几个问题仍未得到解答，尤其是在反应的生化预测指标方面。
在本文中，我们将讨论关于HCC免疫治疗反应预测生物标志物的现有证据。2022年1月在Pubmed/Medline、Cochrane图书馆和Scopus数据库中进行了文献检索。
在接受ICI的HCC患者中，预测生物标志物的识别是一个未满足的需求。呼吁HCC医学界进一步努力，以阐明PD-L1表达、肿瘤突变负荷（TMB）、微卫星不稳定性（MSI）、肠道微生物群和其他新兴生物标志物的有效作用。
